ARCHIMED acquires generative AI Diagnostics player Arkstone to support fight against infectious disease

Private equity healthcare specialist ARCHIMED acquired a majority stake in Arkstone Medical Solutions (Arkstone), a pioneer in infectious disease clinical guidance and antimicrobial stewardship based on machine learning (ML) and generative artificial intelligence (gen AI).

Florida-based Arkstone was created in 2018 by three co-founders with backgrounds in software, clinical content, and customer operations. The company provides Clinical Decision Support powered by Machine Learning (ML) and generative Artificial Intelligence (gen AI), helping healthcare providers optimize antimicrobial use. Arkstone’s flagship OneChoice Report leverages ML and gen AI to provide optimal infectious disease treatment recommendations. OneChoice analyses laboratory results alongside patient data and delivers guidance to clinicians. Already in use by over 150 laboratories across the US and internationally, Arkstone is transforming how healthcare providers diagnose, treat, and understand infectious diseases.

Arkstone is at the junction of ARCHIMED’s Healthcare IT and Diagnostics sectors. It operates in a prioritized sub-sector identified thanks to ARCHIMED’s MedSeg tool. The investment opportunity was sourced directly by the team after being screened and identified as a category leader through ARCHIMED’s MedDiscover approach.

This transaction reflects ARCHIMED’s ability to respond to public health issues – which was already the case through its investment in Testing player CARSO.

MED Rise is ARCHIMED’s 2024 small-cap buyout fund. ARCHIMED can invest from €10 million to €1 billion per investment through its different fund lines.

All fully deployed ARCHIMED funds have top decile performance, especially from a DPI perspective (Source: PitchBook) and ARCHIMED was ranked as the world’s 6th best performing Buyout firm in the 2023 HEC-DowJones ranking (out of 632 Buyout firms globally).